UTHR UNITED THERAPEUTICS Corp

Price (delayed)

$197.86

Market cap

$8.86B

P/E Ratio

21.65

Dividend/share

N/A

EPS

$9.14

Enterprise value

$8.83B

Sector: Healthcare
Industry: Biotechnology

United Therapeutics Corporation focuses on the strength of a balanced, value-creating biotechnology model. We are confident in our future thanks to our fundamental attributes, namely our obsession with quality and ...

Highlights

The equity has increased by 17% year-on-year
The company's gross profit rose by 5% YoY
The stock's P/E is 104% above its 5-year quarterly average of 10.4 and 59% above its last 4 quarters average of 13.3
The quick ratio has declined by 24% year-on-year

Key stats

What are the main financial stats of UTHR
Market
Shares outstanding
44.8M
Market cap
$8.86B
Enterprise value
$8.83B
Valuations
Price to earnings (P/E)
21.65
Price to book (P/B)
2.56
Price to sales (P/S)
5.86
EV/EBIT
16.99
EV/EBITDA
15.5
EV/Sales
5.86
Earnings
Revenue
$1.51B
EBIT
$519.7M
EBITDA
$569.7M
Free cash flow
$576.4M
Per share
EPS
$9.14
Free cash flow per share
$12.92
Book value per share
$77.35
Revenue per share
$33.77
TBVPS
$103.06
Balance sheet
Total assets
$4.64B
Total liabilities
$1.2B
Debt
$800M
Equity
$3.45B
Working capital
$1.71B
Liquidity
Debt to equity
0.23
Current ratio
6.66
Quick ratio
6.19
Net debt/EBITDA
-0.06
Margins
EBITDA margin
37.8%
Gross margin
92.8%
Net margin
26.9%
Operating margin
24%
Efficiency
Return on assets
9.1%
Return on equity
12.3%
Return on invested capital
12.6%
Return on capital employed
12%
Return on sales
34.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

UTHR stock price

How has the UNITED THERAPEUTICS stock price performed over time
Intraday
2.11%
1 week
1.25%
1 month
-2.43%
1 year
74.43%
YTD
30.35%
QTD
18.29%

Financial performance

How have UNITED THERAPEUTICS's revenue and profit performed over time
Revenue
$1.51B
Gross profit
$1.4B
Operating income
$362.1M
Net income
$405.4M
Gross margin
92.8%
Net margin
26.9%
The company's operating margin fell by 45% YoY and by 40% QoQ
The operating income has contracted by 43% YoY and by 39% from the previous quarter
The net margin has contracted by 27% YoY and by 22% from the previous quarter
UNITED THERAPEUTICS's net income has decreased by 23% YoY and by 21% QoQ

Growth

What is UNITED THERAPEUTICS's growth rate over time

Valuation

What is UNITED THERAPEUTICS stock price valuation
P/E
21.65
P/B
2.56
P/S
5.86
EV/EBIT
16.99
EV/EBITDA
15.5
EV/Sales
5.86
The stock's P/E is 104% above its 5-year quarterly average of 10.4 and 59% above its last 4 quarters average of 13.3
The company's EPS fell by 24% YoY and by 22% QoQ
UTHR's price to book (P/B) is 39% higher than its last 4 quarters average of 1.8 and 14% higher than its 5-year quarterly average of 2.2
The equity has increased by 17% year-on-year
The stock's P/S is 74% above its 5-year quarterly average of 3.3 and 40% above its last 4 quarters average of 4.1
The company's revenue rose by 4.4% YoY

Efficiency

How efficient is UNITED THERAPEUTICS business performance
The ROIC has contracted by 37% YoY and by 25% from the previous quarter
The ROE has contracted by 36% YoY and by 24% from the previous quarter
UNITED THERAPEUTICS's return on assets has decreased by 32% YoY and by 24% QoQ
The company's return on sales fell by 29% YoY and by 23% QoQ

Dividends

What is UTHR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for UTHR.

Financial health

How did UNITED THERAPEUTICS financials performed over time
The current ratio has contracted by 25% YoY
The quick ratio has declined by 24% year-on-year
The debt is 77% less than the equity
The equity has increased by 17% year-on-year
UNITED THERAPEUTICS's debt to equity has decreased by 15% YoY and by 4.2% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.